Skip to content
Screener

SG&A at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
$577.2M-0.4%
Sotera Health logo
Sotera HealthSHC
$68.16M-1.1%
Fortrea Holdings Inc. logo
Fortrea Holdings Inc.FTRE
$102.1M-18.2%
Revvity logo
RevvityRVTY
$253.88M+1.7%
IQVIA logo
IQVIAIQV
$574M+12.8%
Quest Diagnostics logo
Quest DiagnosticsDGX
$529M+8.8%

Segments

By segment

See full
DSA$60.12M-0.3%
Manufacturing$35.89M+10.7%
RMS$26.5M-6.6%

Other financials

Income statement

See full
Revenue$1.0B-2.7%
Gross profit$349.0M-3.5%
Operating income$119.9M+19.7%
Net income-$1.5M-103%
EPS (diluted)-$0.03-103%

Balance sheet

See full
Cash & equivalents$240.6M+30.2%
Total debt$3.0B+8.1%
Total equity$2.8B-15.3%
Total assets$7.5B-0.4%

Cash flow

See full
Operating cash flow$179.7M-12.2%
CapEx$31.1M-11.9%
Free cash flow$148.6M-12.2%

Valuation

See full
Market cap$12.56B+70.1%
Enterprise value$15.36B+53.4%
P/S3.1×+1.3×

Profitability

See full
Gross margin84.7%
Operating margin13%-2.4pp
Net margin-6%
FCF margin9.3%-5.1pp

Returns & leverage

See full
Return on equity-7.7%
Debt / equity1.1×+0.2×
Current ratio1.3×0.0×

Where this comes from

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The source filing: Charles River Laboratories’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 9:21 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001100682-26-000118
Line itemThree Months Ended / June 27, 2026Three Months Ended / June 28, 2025Six Months Ended / June 27, 2026Six Months Ended / June 28, 2025
Costs and expenses
Cost of services provided (excluding amortization of intangible assets)552,007584,8761,160,9141,162,304
Cost of products sold (excluding amortization of intangible assets)88,69790,192180,956179,200
Selling, general and administrative228,897191,549388,319369,348
Amortization of intangible assets14,58965,38429,934130,648
Operating income119,888100,134239,785174,803
Other income (expense)
Interest income1,0321,0972,0652,501

Item 1. Financial Statements

FAQ

What is Charles River Laboratories's SG&A?
Charles River Laboratories (CRL) reported SG&A of $228.9M in Q2 2026.
How has Charles River Laboratories's SG&A changed year-over-year?
Charles River Laboratories's SG&A increased by 19.5% year-over-year, from $191.55M to $228.9M.
What is the long-term trend for Charles River Laboratories's SG&A?
Over 4 years (2021 to 2025), Charles River Laboratories's SG&A has grown at a 4.6% compound annual growth rate (CAGR), from $619.92M to $743.07M.
What does SG&A mean?
Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Ask your AI about Charles River Laboratories's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude